Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Rheumatoid Arthritis

  Free Subscription


Articles published in Clin Exp Rheumatol

Retrieve available abstracts of 282 articles:
HTML format
Text format



Single Articles


    October 2019
  1. CHUNG HY, Wickel J, Stuhlmuller B, Kinne RW, et al
    Acid sphingomyelinase activity is elevated in serum of rheumatoid arthritis patients, suppressed by anti-TNF-alpha treatment.
    Clin Exp Rheumatol. 2019 Oct 8. pii: 13791.
    PubMed     Text format    


  2. CIOFFI G, Giollo A, Orsolini G, Idolazzi L, et al
    Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction.
    Clin Exp Rheumatol. 2019 Oct 1. pii: 14158.
    PubMed     Text format     Abstract available


    September 2019
  3. ACEBES C, Andreu JL, Balsa A, Batlle E, et al
    "There is something you must see": breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective.
    Clin Exp Rheumatol. 2019 Sep 18. pii: 13708.
    PubMed     Text format     Abstract available


  4. BELLAN M, Andreoli L, Nerviani A, Piantoni S, et al
    Is cholecalciferol a potential disease modifying anti-rheumatic drug for the management of rheumatoid arthritis?
    Clin Exp Rheumatol. 2019 Sep 17. pii: 14032.
    PubMed     Text format     Abstract available


  5. FORMAN M, Leatherwood C, Iversen MD, Solomon DH, et al
    Quality improvement for rheumatoid arthritis care: results from a focus group.
    Clin Exp Rheumatol. 2019 Sep 13. pii: 14182.
    PubMed     Text format     Abstract available


  6. KRASSELT M, Baerwald C, Seifert O
    Hypogammaglobulinaemia in identical twin sisters with rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Sep 10. pii: 14218.
    PubMed     Text format    


  7. RUWAARD J, Marsman AF, Nurmohamed MT, van der Horst-Bruinsma IE, et al
    Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.
    Clin Exp Rheumatol. 2019;37:756-761.
    PubMed     Text format     Abstract available


  8. MARTIN-MARTINEZ MA, Castaneda S, Gonzalez-Juanatey C, Sanchez-Alonso F, et al
    Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project.
    Clin Exp Rheumatol. 2019;37:731-739.
    PubMed     Text format     Abstract available


  9. PINCUS T, Castrejon I, Yazici Y, Gibson KA, et al
    Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease.
    Clin Exp Rheumatol. 2019;37 Suppl 120:7-17.
    PubMed     Text format     Abstract available


    August 2019
  10. AHN JK, Kim J, Cheong YE, Kim KH, et al
    Variation in the synovial fluid metabolome according to disease activity of rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Aug 27. pii: 14333.
    PubMed     Text format     Abstract available


  11. ISSA SF, Lindegaard HM, Lorenzen T, Junker K, et al
    Increased serum levels of microfibrillar-associated protein 4 (MFAP4) are not associated with clinical synovitis in rheumatoid arthritis but may reflect underlying cardiovascular comorbidity.
    Clin Exp Rheumatol. 2019 Aug 27. pii: 13860.
    PubMed     Text format     Abstract available


  12. ERRE GL, Piras A, Piga M, Fedele AL, et al
    QT and QT dispersion intervals in long-standing and moderately active rheumatoid arthritis: results from a multicentre cross-sectional study.
    Clin Exp Rheumatol. 2019 Aug 27. pii: 14310.
    PubMed     Text format     Abstract available


  13. CHENG L, Qian L
    Reply to J. Gao's commentary on: Aromatic hydrocarbon receptor provides a link between smoking and rheumatoid arthritis in peripheral blood mononuclear cells.
    Clin Exp Rheumatol. 2019 Aug 15. pii: 14657.
    PubMed     Text format    


  14. ZHOU L, Wang J, Gao J
    Aromatic hydrocarbon receptor provides a link between smoking and rheumatoid arthritis in peripheral blood mononuclear cells: a commentary.
    Clin Exp Rheumatol. 2019 Aug 14. pii: 14451.
    PubMed     Text format    


  15. PETRACKOVA A, Horak P, Radvansky M, Fillerova R, et al
    Revealed heterogeneity in rheumatoid arthritis based on multivariate innate signature analysis.
    Clin Exp Rheumatol. 2019 Aug 3. pii: 14171.
    PubMed     Text format     Abstract available


    July 2019
  16. ZABOTTI A, Finzel S, Baraliakos X, Aouad K, et al
    Imaging in the preclinical phases of rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Jul 25. pii: 14199.
    PubMed     Text format     Abstract available


  17. DORIA A, Zavaglia D
    Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
    Clin Exp Rheumatol. 2019 Jul 22. pii: 13054.
    PubMed     Text format     Abstract available


  18. LI Z, Niu H, Yao H, Chen M, et al
    IL-17A upregulates P-glycoprotein expression in peripheral blood lymphocytes of patients with rheumatoid arthritis through TAK1.
    Clin Exp Rheumatol. 2019 Jul 19. pii: 13728.
    PubMed     Text format     Abstract available


  19. SILVA CFR, Duarte C, Ferreira RJO, Santos E, et al
    Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model.
    Clin Exp Rheumatol. 2019 Jul 19. pii: 13806.
    PubMed     Text format     Abstract available


  20. LOPEZ J, Merino L, Piris L, Herrera FS, et al
    Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment.
    Clin Exp Rheumatol. 2019;37:615-622.
    PubMed     Text format     Abstract available


  21. BERTHELOT JM, Bart G, Darrieutort-Lafitte C, Le Goff B, et al
    Pain catastrophising worsens RAPID3 in all rheumatologic conditions.
    Clin Exp Rheumatol. 2019;37:600-607.
    PubMed     Text format     Abstract available


    June 2019
  22. REICHERT S, Jurianz E, Natalie P, Schlumberger W, et al
    Is periodontitis a prognostic factor in order to indicate antibodies against citrullinated peptides in patients with rheumatoid arthritis?
    Clin Exp Rheumatol. 2019 Jun 19. pii: 13892.
    PubMed     Text format     Abstract available


  23. SHAN L, van den Hoogen LL, Meeldijk J, Kok HM, et al
    Increased intra-articular granzyme M may trigger local IFN-lambda1/IL-29 response in rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Jun 6. pii: 13221.
    PubMed     Text format     Abstract available


  24. GIUSTI A, Epis OM, Migliore A, Ricioppo A, et al
    The effect of gender on methotrexate prescription attitudes in Italian rheumatoid arthritis patients: the MARI study.
    Clin Exp Rheumatol. 2019 Jun 6. pii: 13594.
    PubMed     Text format     Abstract available


  25. PAREDES S, Taverner D, Ferre R, Alegret JM, et al
    MicroRNA differential expression shared between rheumatoid arthritis and acute myocardial infarction: an exploratory study.
    Clin Exp Rheumatol. 2019 Jun 3. pii: 14068.
    PubMed     Text format    


    May 2019
  26. SILVAGNI E, Di Battista M, Bonifacio AF, Zucchi D, et al
    One year in review 2019: novelties in the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 May 24. pii: 14163.
    PubMed     Text format     Abstract available


  27. PAALANEN K, Rannio K, Rannio T, Asikainen J, et al
    Prevalence of calcium pyrophosphate deposition disease in a cohort of patients diagnosed with seronegative rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 May 22. pii: 13723.
    PubMed     Text format     Abstract available


  28. ASSMANN G, Zinke S, Gerling M, Bittenbring JT, et al
    Progranulin-autoantibodies in sera of rheumatoid arthritis patients negative for rheumatoid factor and anti-citrullinated peptide antibodies.
    Clin Exp Rheumatol. 2019 May 10. pii: 13896.
    PubMed     Text format     Abstract available


  29. CROIA C, Bursi R, Sutera D, Petrelli F, et al
    One year in review 2019: pathogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2019;37:347-357.
    PubMed     Text format     Abstract available


  30. ENDO Y, Koga T, Tsutsui S, Ashizawa K, et al
    Lung consolidation and mediastinal lymphadenopathy in patients with early anti-citrullinated protein antibody-positive rheumatoid arthritis.
    Clin Exp Rheumatol. 2019;37:517-518.
    PubMed     Text format    


  31. DI MUNNO O, Ferro F
    The effect of biologic agents on bone homeostasis in chronic inflammatory rheumatic diseases.
    Clin Exp Rheumatol. 2019;37:502-507.
    PubMed     Text format     Abstract available


  32. GRIGORIADOU S, Chowdhury F, Pontarini E, Tappuni A, et al
    B cell depletion with rituximab in the treatment of primary Sjogren's syndrome: what have we learnt?
    Clin Exp Rheumatol. 2019;37 Suppl 118:217-224.
    PubMed     Text format     Abstract available


  33. CECCHETTINI A, Finamore F, Puxeddu I, Ferro F, et al
    Salivary extracellular vesicles versus whole saliva: new perspectives for the identification of proteomic biomarkers in Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:240-248.
    PubMed     Text format     Abstract available


  34. SEGHIERI C, Lupi E, Exarchos TP, Ferro F, et al
    Variation in primary Sjogren's syndrome care among European countries.
    Clin Exp Rheumatol. 2019;37 Suppl 118:27-28.
    PubMed     Text format    


  35. BARTOLONI E, Baldini C, Ferro F, Alunno A, et al
    Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjogren's syndrome: a novel pathogenetic scenario?
    Clin Exp Rheumatol. 2019;37 Suppl 118:133-139.
    PubMed     Text format     Abstract available


  36. GANDOLFO S, De Vita S
    Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:199-208.
    PubMed     Text format     Abstract available


  37. ALUNNO A, Carubbi F, Bartoloni E, Cipriani P, et al
    The kaleidoscope of neurological manifestations in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:192-198.
    PubMed     Text format     Abstract available


  38. CAFARO G, Croia C, Argyropoulou OD, Leone MC, et al
    One year in review 2019: Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:3-15.
    PubMed     Text format     Abstract available


  39. HARRIS VM, Scofield RH, Sivils KL
    Genetics in Sjogren's syndrome: where we are and where we go.
    Clin Exp Rheumatol. 2019;37 Suppl 118:234-239.
    PubMed     Text format     Abstract available


  40. GOULES A, Geetha D, Arend LJ, Baer AN, et al
    Renal involvement in primary Sjogren's syndrome: natural history and treatment outcome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:123-132.
    PubMed     Text format     Abstract available


  41. TZIOUFAS AG, Goules AV
    The necessity of novel biomarkers in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:16-18.
    PubMed     Text format    


  42. DE VITA S, Zabotti A, Gandolfo S
    Current limitations and ongoing initiatives to evaluate the activity, damage and outcome of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:24-26.
    PubMed     Text format    


  43. RAMOS-CASALS M, Maria A, Suarez-Almazor ME, Lambotte O, et al
    Sicca/Sjogren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).
    Clin Exp Rheumatol. 2019;37 Suppl 118:114-122.
    PubMed     Text format     Abstract available


  44. ACAR-DENIZLI N, Kostov B, Ramos-Casals M
    The Big Data Sjogren Consortium: a project for a new data science era.
    Clin Exp Rheumatol. 2019;37 Suppl 118:19-23.
    PubMed     Text format    


  45. GANDOLFO S, Bulfoni M, Fabro C, Russi S, et al
    Thymic stromal lymphopoietin expression from benign lymphoproliferation to malignant B-cell lymphoma in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:55-64.
    PubMed     Text format     Abstract available


  46. MAARSE F, Jager DHJ, Alterch S, Korfage A, et al
    Sjogren's syndrome is not a risk factor for periodontal disease: a systematic review.
    Clin Exp Rheumatol. 2019;37 Suppl 118:225-233.
    PubMed     Text format     Abstract available


  47. HAMMENFORS DS, Causevic H, Assmus J, Brun JG, et al
    Assessment of major salivary gland ultrasonography in Sjogren's syndrome. A comparison between bedside and post-examination evaluations.
    Clin Exp Rheumatol. 2019;37 Suppl 118:153-158.
    PubMed     Text format     Abstract available


  48. ARGYROPOULOU OD, Chatzis LG, Rontogianni D, Tzioufas AG, et al
    Autoimmune epithelitis beyond the exocrine glands: an unusual case of anti-Ro/La and Scl-70 lymphocytic interstitial pneumonia.
    Clin Exp Rheumatol. 2019;37 Suppl 118:249-251.
    PubMed     Text format     Abstract available


  49. RETAMOZO S, Acar-Denizli N, Rasmussen A, Horvath IF, et al
    Systemic manifestations of primary Sjogren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients.
    Clin Exp Rheumatol. 2019;37 Suppl 118:97-106.
    PubMed     Text format     Abstract available


  50. GOULES AV, Exarchos TP, Pezoulas VC, Kourou KD, et al
    Sjogren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts.
    Clin Exp Rheumatol. 2019;37 Suppl 118:175-184.
    PubMed     Text format     Abstract available


  51. MARKETOS N, Cinoku I, Rapti A, Mavragani CP, et al
    Type I interferon signature in Sjogren's syndrome: pathophysiological and clinical implications.
    Clin Exp Rheumatol. 2019;37 Suppl 118:185-191.
    PubMed     Text format     Abstract available


  52. PARK Y, Lee J, Koh JH, Sung YK, et al
    Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjogren's syndrome: data from a nationwide cohort for Sjogren's syndrome in Korea.
    Clin Exp Rheumatol. 2019;37 Suppl 118:107-113.
    PubMed     Text format     Abstract available


  53. XIAO F, Han M, Wang X, Gong X, et al
    Animal models of Sjogren's syndrome: an update.
    Clin Exp Rheumatol. 2019;37 Suppl 118:209-216.
    PubMed     Text format     Abstract available


  54. ZABOTTI A, Zandonella Callegher S, Gandolfo S, Valent F, et al
    Hyperechoic bands detected by salivary gland ultrasonography are related to salivary impairment in established Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:146-152.
    PubMed     Text format     Abstract available


  55. LEWIS I, Hackett KL, Ng WF, Ellis J, et al
    A two-phase cohort study of the sleep phenotype within primary Sjogren's syndrome and its clinical correlates.
    Clin Exp Rheumatol. 2019;37 Suppl 118:78-82.
    PubMed     Text format     Abstract available


  56. CALLHOFF J, Thiele K, Dorner T, Zink A, et al
    Trends in employment and hospitalisation in patients with Sjogren's syndrome 1996-2016: results from the German National database.
    Clin Exp Rheumatol. 2019;37 Suppl 118:83-89.
    PubMed     Text format     Abstract available


  57. INANC N, Sahinkaya Y, Mumcu G, Ture Ozdemir F, et al
    Evaluation of salivary gland ultrasonography in primary Sjogren's syndrome: does it reflect clinical activity and outcome of the disease?
    Clin Exp Rheumatol. 2019;37 Suppl 118:140-145.
    PubMed     Text format     Abstract available


  58. PEZOULAS VC, Kourou KD, Kalatzis F, Exarchos TP, et al
    Enhancing medical data quality through data curation: a case study in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:90-96.
    PubMed     Text format     Abstract available


  59. VAN GINKEL MS, Haacke EA, Bootsma H, Arends S, et al
    Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjogren's syndrome patients.
    Clin Exp Rheumatol. 2019;37 Suppl 118:42-48.
    PubMed     Text format     Abstract available


  60. FASANO S, Isenberg DA
    Present and novel biologic drugs in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:167-174.
    PubMed     Text format     Abstract available


  61. SPOERL D, Roux-Lombard P
    Are antibodies against La (SSB) no longer useful for the diagnosis of Sjogren's syndrome?
    Clin Exp Rheumatol. 2019;37 Suppl 118:252-253.
    PubMed     Text format    


  62. YAN T, Shen J, Chen J, Zhao M, et al
    Differential expression of miR-17-92 cluster among varying histological stages of minor salivary gland in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:49-54.
    PubMed     Text format     Abstract available


  63. VINCENT FB, Bubicich M, Downie-Doyle S, Mackay F, et al
    Serum soluble Fas and Fas ligand (FasL) in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:254-256.
    PubMed     Text format    


  64. TALOTTA R, Mercurio V, Bongiovanni S, Vittori C, et al
    Evaluation of salivary and plasma microRNA expression in patients with Sjogren's syndrome, and correlations with clinical and ultrasonographic outcomes.
    Clin Exp Rheumatol. 2019;37 Suppl 118:70-77.
    PubMed     Text format     Abstract available


  65. OLIVARES-MARTINEZ E, Hernandez-Ramirez DF, Nunez-Alvarez CA, Llorente L, et al
    alpha-enolase is an antigenic target in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2019;37 Suppl 118:29-35.
    PubMed     Text format     Abstract available


  66. ALUNNO A, Ibba-Manneschi L, Bistoni O, Cipriani S, et al
    Angiogenic T cells in primary Sjogren's syndrome: a double-edged sword?
    Clin Exp Rheumatol. 2019;37 Suppl 118:36-41.
    PubMed     Text format     Abstract available


  67. MORENO-QUISPE LA, Velarde-Grados IVN, Guzman-Avalos M, De Arriba L, et al
    Prevalence of sicca syndrome in the Peruvian population.
    Clin Exp Rheumatol. 2019;37 Suppl 118:65-69.
    PubMed     Text format     Abstract available


    April 2019
  68. NIU HQ, Li ZH, Zhao WP, Zhao XC, et al
    Sirolimus selectively increases circulating Treg cell numbers and restores the Th17/Treg balance in rheumatoid arthritis patients with low disease activity or in DAS28 remission who previously received conventional disease-modifying anti-rheumatic dru
    Clin Exp Rheumatol. 2019 Apr 29. pii: 13762.
    PubMed     Text format     Abstract available


  69. DORNER T, Schulze-Koops H, Burmester GR, Iking-Konert C, et al
    Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
    Clin Exp Rheumatol. 2019 Apr 16. pii: 13332.
    PubMed     Text format     Abstract available


  70. ALVAREZ-CIENFUEGOS A, Cantero-Nieto L, Garcia-Gomez JA, Robledo G, et al
    FGF23-Klotho axis in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Apr 16. pii: 13821.
    PubMed     Text format     Abstract available


  71. LIU R, Zhao P, Zhang Q, Che N, et al
    Adiponectin promotes fibroblast-like synoviocytes producing IL-6 to enhance T follicular helper cells response in rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Apr 11. pii: 13169.
    PubMed     Text format     Abstract available


  72. SKAPENKO A, Smolen JS, Kavanaugh A, Arora V, et al
    Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate-treated rheumatoid arthritis patients in OPTIMA.
    Clin Exp Rheumatol. 2019 Apr 9. pii: 13260.
    PubMed     Text format     Abstract available


  73. SZEKANECZ Z, Koncz A, Dunkel J, Vencovsky J, et al
    Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study.
    Clin Exp Rheumatol. 2019 Apr 9. pii: 13453.
    PubMed     Text format     Abstract available


    March 2019
  74. ZHENG LX, Li KX, Hong FF, Yang SL, et al
    Pain and bone damage in rheumatoid arthritis: role of leukotriene B4.
    Clin Exp Rheumatol. 2019 Mar 27. pii: 13657.
    PubMed     Text format     Abstract available


  75. OMETTO F, Raffeiner B, Azzolina D, Botsios C, et al
    Adherence in rheumatoid arthritis patients assessed with a validated Italian version of the 5-item Compliance Questionnaire for Rheumatology.
    Clin Exp Rheumatol. 2019 Mar 18. pii: 13195.
    PubMed     Text format     Abstract available


  76. FECHTNER SC, Singh AK, Ahmed S
    Role of cannabinoid receptor 2 in mediating interleukin-1beta-induced inflammation in rheumatoid arthritis synovial fibroblasts.
    Clin Exp Rheumatol. 2019 Mar 18. pii: 13546.
    PubMed     Text format     Abstract available


  77. BEN KILANI MS, Cornelis F, Olaso R, Chaudru V, et al
    Investigation of candidate gene copy number identifies FCGR3B as a potential biomarker for rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Mar 7. pii: 13412.
    PubMed     Text format     Abstract available


  78. BURMESTER G, Nusslein H, von Hinuber U, Detert J, et al
    Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FalphasT study.
    Clin Exp Rheumatol. 2019 Mar 7. pii: 13055.
    PubMed     Text format     Abstract available


    February 2019
  79. TURK SA, Heslinga M, Twisk J, van der Lugt V, et al
    Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Feb 15. pii: 12496.
    PubMed     Text format    


  80. UMEKITA K, Miyauchi S, Nomura H, Umeki K, et al
    Neutrophil-derived lactoferrin induces the inflammatory responses of rheumatoid arthritis synovial fibroblasts via Toll-like receptor 4.
    Clin Exp Rheumatol. 2019 Feb 11. pii: 13033.
    PubMed     Text format     Abstract available


  81. KWON OC, Oh JS, Hong S, Lee CK, et al
    Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide.
    Clin Exp Rheumatol. 2019 Feb 11. pii: 13514.
    PubMed     Text format     Abstract available


  82. LIU S, Li Y, Xia L, Shen H, et al
    IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Feb 11. pii: 13331.
    PubMed     Text format     Abstract available


  83. CHOY EHS, Miceli-Richard C, Gonzalez-Gay MA, Sinigaglia L, et al
    The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
    Clin Exp Rheumatol. 2019 Feb 11. pii: 13262.
    PubMed     Text format     Abstract available


  84. TWEEHUYSEN L, den Broeder AA, Schraa K, Netea MG, et al
    Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Feb 7. pii: 12631.
    PubMed     Text format     Abstract available


    January 2019
  85. BAKER JF, Stokes A, Mikuls TR, George M, et al
    Current and early life weight and associations with mortality in rheumatoid arthritis.
    Clin Exp Rheumatol. 2019 Jan 18. pii: 13490.
    PubMed     Text format     Abstract available


  86. KOTYLA PJ
    Insulin resistance vary across connective tissue diseases patients: comparison between rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis.
    Clin Exp Rheumatol. 2019 Jan 10. pii: 12876.
    PubMed     Text format    


  87. PROVAN SA, Austad C, Halsaa V, Hammer HB, et al
    Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register.
    Clin Exp Rheumatol. 2019 Jan 8. pii: 13149.
    PubMed     Text format     Abstract available


  88. CARLSON AK, Rawle RA, Wallace CW, Adams E, et al
    Global metabolomic profiling of human synovial fluid for rheumatoid arthritis biomarkers.
    Clin Exp Rheumatol. 2019 Jan 3. pii: 12929.
    PubMed     Text format     Abstract available


    December 2018
  89. PASCUAL-RAMOS V, Contreras-Yanez I, Ruiz D, de la Luz Casas-Martinez M, et al
    Attitudes about principle of autonomy in Hispanic patients from a dynamic early rheumatoid arthritis cohort.
    Clin Exp Rheumatol. 2018 Dec 20. pii: 13103.
    PubMed     Text format     Abstract available


  90. MANZO C
    Are the cognitive functions of patients with rheumatoid arthritis associated with disease activity, with carotid atherosclerotic changes or with mood disorders such as depression and anxiety?
    Clin Exp Rheumatol. 2018 Dec 20. pii: 13520.
    PubMed     Text format    


  91. CLEUTJENS FAHM, Boonen AERCH, van Onna MGB
    Geriatric syndromes in patients with rheumatoid arthritis: a literature overview.
    Clin Exp Rheumatol. 2018 Dec 19. pii: 12837.
    PubMed     Text format     Abstract available


    November 2018
  92. HAIDER S, Grabovac I, Berner C, Lamprecht T, et al
    Frailty in seropositive rheumatoid arthritis patients of working age: a cross-sectional study.
    Clin Exp Rheumatol. 2018 Nov 19. pii: 13053.
    PubMed     Text format     Abstract available


  93. PONGRATZ G, Lowin T, Sewerin P, Zaucke F, et al
    Tryptophan metabolism in rheumatoid arthritis is associated with rheumatoid factor and predicts joint pathology evaluated by the Rheumatoid Arthritis MRI Score (RAMRIS).
    Clin Exp Rheumatol. 2018 Nov 16. pii: 12776.
    PubMed     Text format     Abstract available


  94. SANTOS EF, Duarte CM, Ferreira RO, Pinto AM, et al
    Multifactorial explanatory model of depression in patients with rheumatoid arthritis: a structural equation approach.
    Clin Exp Rheumatol. 2018 Nov 12. pii: 13143.
    PubMed     Text format     Abstract available


  95. STEVER JR, Cannon GW, Teng CC, Accortt NA, et al
    Utility of administrative and clinical data to predict major change in medical treatment in US Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.
    Clin Exp Rheumatol. 2018 Nov 12. pii: 12960.
    PubMed     Text format     Abstract available


  96. CASTANEDA S, Remuzgo-Martinez S, Lopez-Mejias R, Genre F, et al
    Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Nov 7. pii: 12890.
    PubMed     Text format     Abstract available


  97. MCCULLEY CB, Barton JL, Cannon GW, Sauer BC, et al
    Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Nov 7. pii: 12862.
    PubMed     Text format     Abstract available


  98. MORTENSEN JH, Guo X, De Los Reyes M, Dziegiel MH, et al
    The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRalpha-mAb treatment in rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2018 Nov 7. pii: 12587.
    PubMed     Text format     Abstract available


  99. NAREDO E, Rutigliano IM, Janta I, Scirocco C, et al
    Agreement between semiquantitative and quantitative Doppler scoring systems for the assessment of synovial pathological vascularisation in rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Nov 5. pii: 12442.
    PubMed     Text format     Abstract available


  100. KIM MJ, Ahn EY, Hwang W, Lee Y, et al
    Association between fever pattern and clinical manifestations of adult-onset Still's disease: unbiased analysis using hierarchical clustering.
    Clin Exp Rheumatol. 2018;36.
    PubMed     Text format     Abstract available


    October 2018
  101. CHENG L, Qian L, Xu ZZ, Tan Y, et al
    Aromatic hydrocarbon receptor provides a link between smoking and rheumatoid arthritis in peripheral blood mononuclear cells.
    Clin Exp Rheumatol. 2018 Oct 22. pii: 12789.
    PubMed     Text format     Abstract available


  102. SAKELLARIOU G, Lombardi G, Vitolo B, Gomarasca M, et al
    Serum calprotectin as a marker of clinical and ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.
    Clin Exp Rheumatol. 2018 Oct 8. pii: 12977.
    PubMed     Text format     Abstract available


    September 2018
  103. MERONI PL, Zavaglia D, Girmenia C
    Reply to: Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Sep 20. pii: 13153.
    PubMed     Text format    


  104. IHDAYHID D, Edelman J, Keen HI
    Hepatitis B virus vaccination in an Australian pre-biologic population with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Sep 20. pii: 12600.
    PubMed     Text format    


  105. TEJERA-SEGURA B, Lopez-Mejias R, de Vera-Gonzalez A, Delgado-Gonzalez A, et al
    Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Sep 17. pii: 12775.
    PubMed     Text format     Abstract available


  106. PABLOS JL, Navarro F, Blanco FJ, Roman-Ivorra JA, et al
    Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
    Clin Exp Rheumatol. 2018 Sep 17. pii: 12814.
    PubMed     Text format     Abstract available


  107. BAKER JF, Conaghan PG, Gandjbakhch F
    Update on magnetic resonance imaging and ultrasound in rheumatoid arthritis.
    Clin Exp Rheumatol. 2018;36 Suppl 114:16-23.
    PubMed     Text format     Abstract available


  108. NIEMANTSVERDRIET E, van der Helm-van Mil AHM
    Imaging detected tenosynovitis of metacarpophalangeal and wrist joints: an increasingly recognised characteristic of rheumatoid arthritis.
    Clin Exp Rheumatol. 2018;36 Suppl 114:131-138.
    PubMed     Text format     Abstract available


  109. LUCIANO N, Ferro F, Bombardieri S, Baldini C, et al
    Advances in salivary gland ultrasonography in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 114:159-164.
    PubMed     Text format     Abstract available


  110. FANOURIAKIS A, Papalopoulos I, Gergianaki I, Spyrou G, et al
    In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
    Clin Exp Rheumatol. 2018;36:806-813.
    PubMed     Text format     Abstract available


    August 2018
  111. CAPORALI R, Zavaglia D
    Real-world experience with tofacitinib for treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Aug 29. pii: 12905.
    PubMed     Text format     Abstract available


  112. BARBER CEH, Sandhu N, Rankin JA, MacMullan P, et al
    Rheum4U: Development and testing of a web-based tool for improving the quality of care for patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Aug 29. pii: 12878.
    PubMed     Text format     Abstract available


  113. GENG Z, Yu Y, Hu S, Dong L, et al
    Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials.
    Clin Exp Rheumatol. 2018 Aug 29. pii: 12803.
    PubMed     Text format     Abstract available


  114. BI L, Li Y, He L, Xu H, et al
    Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
    Clin Exp Rheumatol. 2018 Aug 29. pii: 12733.
    PubMed     Text format     Abstract available


  115. FIORAVANTI A, Tenti S, Bacarelli MR, Damiani A, et al
    Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition.
    Clin Exp Rheumatol. 2018 Aug 27. pii: 12716.
    PubMed     Text format     Abstract available


  116. BUCH MH, Johnsen A, Schiff M
    Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials.
    Clin Exp Rheumatol. 2018 Aug 21. pii: 12451.
    PubMed     Text format     Abstract available


    July 2018
  117. PASCUAL-RAMOS V, Contreras-Yanez I, Ruiz D, de la Luz Casas-Martinez M, et al
    Reduced quality of life impacts knowledge and type of informed consent in rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2018 Jul 18. pii: 12710.
    PubMed     Text format     Abstract available


  118. CARRARA G, Bortoluzzi A, Sakellariou G, Silvagni E, et al
    Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology.
    Clin Exp Rheumatol. 2018 Jul 18. pii: 12628.
    PubMed     Text format     Abstract available


  119. BORDY R, Verhoeven F, Tournier-Nappey M, Wendling D, et al
    Methotrexate did not improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.
    Clin Exp Rheumatol. 2018 Jul 18. pii: 12603.
    PubMed     Text format     Abstract available


  120. WANG L, Geng Y, Han J, Sun X, et al
    A combination model to predict relapse and successful conventional DMARDs de-escalation in rheumatoid arthritis patients with sustained clinical remission.
    Clin Exp Rheumatol. 2018 Jul 18. pii: 12371.
    PubMed     Text format     Abstract available


  121. SOUBRIER M, Lambert C, Combe B, Gaudin P, et al
    A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Jul 18. pii: 12453.
    PubMed     Text format     Abstract available


  122. ZABOTTI A, Mandl P, Zampogna G, Dejaco C, et al
    One year in review 2018: ultrasonography in rheumatoid arthritis and psoriatic arthritis.
    Clin Exp Rheumatol. 2018;36:519-525.
    PubMed     Text format     Abstract available


  123. FEIST E, Quartier P, Fautrel B, Schneider R, et al
    Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
    Clin Exp Rheumatol. 2018;36:668-675.
    PubMed     Text format     Abstract available


  124. KAWAGUCHI Y, Waguri-Nagaya Y, Tatematsu N, Oguri Y, et al
    The Janus kinase inhibitor tofacitinib inhibits TNF-alpha-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
    Clin Exp Rheumatol. 2018;36:559-567.
    PubMed     Text format     Abstract available


    June 2018
  125. ALOUSH V, Dotan I, Ablin JN, Elkayam O, et al
    Evaluating IBD-specific antiglycan antibodies in serum of patients with spondyloarthritis and rheumatoid arthritis: are they really specific?
    Clin Exp Rheumatol. 2018 Jun 25. pii: 12396.
    PubMed     Text format     Abstract available


  126. PICCHIANTI DIAMANTI A, Navarini L, Messina F, Markovic M, et al
    Ultrasound detection of subclinical synovitis in rheumatoid arthritis patients in clinical remission: a new reduced-joint assessment in 3 target joints.
    Clin Exp Rheumatol. 2018 Jun 14. pii: 12437.
    PubMed     Text format     Abstract available


  127. BAHLAS S, Damiati L, Dandachi N, Sait H, et al
    Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using Luminex Multiple Analyte Profiling technology for precision medicine.
    Clin Exp Rheumatol. 2018 Jun 14. pii: 12385.
    PubMed     Text format     Abstract available


  128. GOOSSENS J, Coustet B, Palazzo E, Dieude P, et al
    Overweight and obesity affect clinical assessment of synovitis in rheumatoid arthritis: comparison of ultrasonography and clinical exam.
    Clin Exp Rheumatol. 2018 Jun 7. pii: 12604.
    PubMed     Text format     Abstract available


  129. PAALANEN K, Rannio K, Rannio T, Asikainen J, et al
    Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study.
    Clin Exp Rheumatol. 2018 Jun 7. pii: 12571.
    PubMed     Text format     Abstract available


  130. WATANABE T, Hattori T, Ogawa Y, Jodo S, et al
    Successful treatment with tofacitinib for renal disorder due to amyloid A amyloidosis and immunoglobulin A nephropathy in a patient with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Jun 7. pii: 12723.
    PubMed     Text format    


  131. SEWERIN P, Muller-Lutz A, Abrar DB, Odendahl S, et al
    Prevention of the progressive biochemical cartilage destruction under methotrexate therapy in early rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Jun 7. pii: 12685.
    PubMed     Text format     Abstract available


    May 2018
  132. LIU R, Zhao P, Tan W, Zhang M, et al
    Cell therapies for refractory rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 May 8. pii: 12448.
    PubMed     Text format     Abstract available


  133. TEITSMA XM, Jacobs JWG, Concepcion AN, Petho-Schramm A, et al
    Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.
    Clin Exp Rheumatol. 2018 May 8. pii: 12447.
    PubMed     Text format     Abstract available


  134. GUDMANN NS, Junker P, Juhl P, Thudium CS, et al
    Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 May 8. pii: 12293.
    PubMed     Text format     Abstract available


  135. BORTOLUZZI A, Furini F, Generali E, Silvagni E, et al
    One year in review 2018: novelties in the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2018;36:347-361.
    PubMed     Text format     Abstract available


  136. RUNOWSKA M, Majewski D, Niklas K, Puszczewicz M, et al
    Chikungunya virus: a rheumatologist's perspective.
    Clin Exp Rheumatol. 2018;36:494-501.
    PubMed     Text format     Abstract available


  137. BAULIER G, Issa N, Gabriel F, Accoceberry I, et al
    Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases.
    Clin Exp Rheumatol. 2018;36:490-493.
    PubMed     Text format     Abstract available


  138. TOLEDANO E, Ortiz AM, Ivorra-Cortes J, Montes N, et al
    Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study.
    Clin Exp Rheumatol. 2018;36:382-388.
    PubMed     Text format     Abstract available


  139. KROESE FGM, Haacke EA, Bombardieri M
    The role of salivary gland histopathology in primary Sjogren's syndrome: promises and pitfalls.
    Clin Exp Rheumatol. 2018;36 Suppl 112:222-233.
    PubMed     Text format     Abstract available


  140. BALDINI C, Ferro F, Luciano N, Bombardieri S, et al
    Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:137-144.
    PubMed     Text format     Abstract available


  141. DE VITA S, Gandolfo S, Zandonella Callegher S, Zabotti A, et al
    The evaluation of disease activity in Sjogren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
    Clin Exp Rheumatol. 2018;36 Suppl 112:150-156.
    PubMed     Text format     Abstract available


  142. ARGYROPOULOU OD, Gunti S, Kapsogeorgou EK, Notkins AL, et al
    Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:239-240.
    PubMed     Text format    


  143. FLORES-CHAVEZ A, Kostov B, Solans R, Fraile G, et al
    Severe, life-threatening phenotype of primary Sjogren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry).
    Clin Exp Rheumatol. 2018;36 Suppl 112:121-129.
    PubMed     Text format     Abstract available


  144. ALUNNO A, Bartoloni E, Valentini V, La Paglia GMC, et al
    Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:210-214.
    PubMed     Text format     Abstract available


  145. BRITO-ZERON P, Retamozo S, Ramos-Casals M
    Phenotyping Sjogren's syndrome: towards a personalised management of the disease.
    Clin Exp Rheumatol. 2018;36 Suppl 112:198-209.
    PubMed     Text format     Abstract available


  146. DELLI K, Dagal EF, Bootsma H, Vissink A, et al
    Patient-reported change of sensibility and pain after parotid and labial gland biopsy applied for primary Sjogren's syndrome diagnostics: one-year follow-up study.
    Clin Exp Rheumatol. 2018;36 Suppl 112:173-176.
    PubMed     Text format     Abstract available


  147. BALDINI C, Zabotti A, Filipovic N, Vukicevic A, et al
    Imaging in primary Sjogren's syndrome: the 'obsolete and the new'.
    Clin Exp Rheumatol. 2018;36 Suppl 112:215-221.
    PubMed     Text format     Abstract available


  148. BOMBARDIERI M, Baldini C, Alevizos I, Akpek E, et al
    Highlights of the 14th International Symposium in Sjogren's Syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:3-13.
    PubMed     Text format    


  149. NOTARSTEFANO C, Croia C, Pontarini E, Lucchesi D, et al
    A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:145-149.
    PubMed     Text format     Abstract available


  150. BRITO-ZERON P, Acar-Denizli N, Ng WF, Zeher M, et al
    How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project).
    Clin Exp Rheumatol. 2018;36 Suppl 112:102-112.
    PubMed     Text format     Abstract available


  151. KIM SY, Lee J, Choi YS, Kim JW, et al
    Do I sound dry? Comparative voice analysis of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:130-136.
    PubMed     Text format     Abstract available


  152. CINOKU I, Mavragani CP, Tellis CC, Nezos A, et al
    Autoantibodies to ox-LDL in Sjogren's syndrome: are they atheroprotective?
    Clin Exp Rheumatol. 2018;36 Suppl 112:61-67.
    PubMed     Text format     Abstract available


  153. ARGYROPOULOU OD, Valentini E, Ferro F, Leone MC, et al
    One year in review 2018: Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:14-26.
    PubMed     Text format     Abstract available


  154. TZIOUFAS AG, Goules AV
    Limited efficacy of targeted treatments in Sjogren's syndrome: why?
    Clin Exp Rheumatol. 2018;36 Suppl 112:27-28.
    PubMed     Text format    


  155. BARTOLONI E, Alunno A, Valentini V, Valentini E, et al
    The prevalence and relevance of traditional cardiovascular risk factors in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:113-120.
    PubMed     Text format     Abstract available


  156. MOUTSOPOULOS HM, Skopouli FN
    Sjogren's syndrome: disease activity indexes! Do they make us better clinicians or technicians?
    Clin Exp Rheumatol. 2018;36 Suppl 112:29-30.
    PubMed     Text format    


  157. KAMPOLIS CF, Fragkioudaki S, Mavragani CP, Zormpala A, et al
    Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:94-101.
    PubMed     Text format     Abstract available


  158. LU C, Wu X, Wen H, Gao H, et al
    Primary myelofibrosis but not autoimmune myelofibrosis accompanied by Sjogren's syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review.
    Clin Exp Rheumatol. 2018;36 Suppl 112:234-236.
    PubMed     Text format     Abstract available


  159. HERNANDEZ-MOLINA G, Valim V, Secco A, Atisha-Fregoso Y, et al
    Do antimalarials protect against damage accrual in primary Sjogren's syndrome? Results from a Latin-American retrospective cohort.
    Clin Exp Rheumatol. 2018;36 Suppl 112:182-185.
    PubMed     Text format     Abstract available


  160. LEE KA, Lee SH, Kim HR
    Diagnostic and predictive evaluation using salivary gland ultrasonography in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:165-172.
    PubMed     Text format     Abstract available


  161. NAKAMURA H, Hasegawa H, Sasaki D, Takatani A, et al
    Detection of human T lymphotropic virus type-I bZIP factor and tax in the salivary glands of Sjogren's syndrome patients.
    Clin Exp Rheumatol. 2018;36 Suppl 112:51-60.
    PubMed     Text format     Abstract available


  162. YONG WC, Sanguankeo A, Upala S
    Association between primary Sjogren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2018;36 Suppl 112:190-197.
    PubMed     Text format     Abstract available


  163. RANTA N, Valli A, Gronholm A, Silvennoinen O, et al
    Proprotein convertase enzyme FURIN is upregulated in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:47-50.
    PubMed     Text format     Abstract available


  164. MOON JS, Shin SY
    Superior oblique myositis causing acquired Brown's syndrome as the first manifestation of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:237-238.
    PubMed     Text format    


  165. AKIYAMA M, Sasaki T, Kaneko Y, Yasuoka H, et al
    Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjogren's syndrome adults from a defined population.
    Clin Exp Rheumatol. 2018;36 Suppl 112:157-164.
    PubMed     Text format     Abstract available


  166. SROKA M, Bagavant H, Biswas I, Ballard A, et al
    Immune response against the coiled coil domain of Sjogren's syndrome associated autoantigen Ro52 induces salivary gland dysfunction.
    Clin Exp Rheumatol. 2018;36 Suppl 112:41-46.
    PubMed     Text format     Abstract available


  167. KARAGEORGAS T, Ioakeimidis D, Mavragani CP
    Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjogren's syndrome: a potential contribution of sleep impairment.
    Clin Exp Rheumatol. 2018;36 Suppl 112:68-72.
    PubMed     Text format     Abstract available


  168. LEEHAN KM, Pezant NP, Rasmussen A, Grundahl K, et al
    Minor salivary gland fibrosis in Sjogren's syndrome is elevated, associated with focus score and not solely a consequence of aging.
    Clin Exp Rheumatol. 2018;36 Suppl 112:80-88.
    PubMed     Text format     Abstract available


  169. ALUNNO A, Bistoni O, Carubbi F, Valentini V, et al
    Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:73-79.
    PubMed     Text format     Abstract available


  170. TORRES-RUIZ J, Faz-Munoz D, Hernandez-Diaz N, Hernandez-Molina G, et al
    Use and withdrawal of immunosuppressors in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:177-181.
    PubMed     Text format     Abstract available


  171. HA YJ, Choi YS, Kang EH, Chung JH, et al
    Increased expression of interferon-lambda in minor salivary glands of patients with primary Sjogren's syndrome and its synergic effect with interferon-alpha on salivary gland epithelial cells.
    Clin Exp Rheumatol. 2018;36 Suppl 112:31-40.
    PubMed     Text format     Abstract available


    April 2018
  172. HACIOGLU A, Hatemi G, Esatoglu SN, Hamuryudan V, et al
    Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study.
    Clin Exp Rheumatol. 2018 Apr 19. pii: 12594.
    PubMed     Text format    


  173. LEE JH, Kim GT, Kim YK, Lee SG, et al
    Cognitive function of patients with rheumatoid arthritis is associated with disease activity but not carotid atherosclerotic changes.
    Clin Exp Rheumatol. 2018 Apr 13. pii: 12306.
    PubMed     Text format     Abstract available


  174. JIAO Y, Ding H, Huang S, Liu Y, et al
    Bcl-XL and Mcl-1 upregulation by calreticulin promotes apoptosis resistance of fibroblast-like synoviocytes via activation of PI3K/Akt and STAT3 pathways in rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Apr 13. pii: 12378.
    PubMed     Text format     Abstract available


  175. KIM SK, Choe JY, Kwak SG, Bae J, et al
    Effect of tumour necrosis factor-alpha inhibitors on renal function in patients with rheumatoid arthritis from the KOBIO registry from 2012 to 2016.
    Clin Exp Rheumatol. 2018 Apr 13. pii: 12359.
    PubMed     Text format     Abstract available


  176. PIANTONI S, Regola F, Scarsi M, Tincani A, et al
    Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abatacept.
    Clin Exp Rheumatol. 2018 Apr 13. pii: 12159.
    PubMed     Text format    


    March 2018
  177. YU C, Li M, Duan X, Fang Y, et al
    Chinese registry of rheumatoid arthritis (CREDIT): Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Mar 21. pii: 12256.
    PubMed     Text format     Abstract available


  178. PASCUAL-RAMOS V, Contreras-Yanez I, Valencia-Quinones KR, Romero-Diaz J, et al
    Rheumatoid arthritis patients achieved better quality of life than systemic lupus erythematosus patients at sustained remission.
    Clin Exp Rheumatol. 2018 Mar 21. pii: 12094.
    PubMed     Text format     Abstract available


  179. GALEAZZI M, Alten R, Chartier M, Elbez Y, et al
    Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
    Clin Exp Rheumatol. 2018 Mar 21. pii: 11733.
    PubMed     Text format    


  180. KUUSELA E, Kouri VP, Olkkonen J, Koivuniemi R, et al
    Serum Epstein-Barr virus DNA, detected by droplet digital PCR, correlates with disease activity in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Mar 20. pii: 12073.
    PubMed     Text format     Abstract available


  181. MENGATO D, Messori A
    Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
    Clin Exp Rheumatol. 2018 Mar 20. pii: 11928.
    PubMed     Text format    


  182. COMBE B, Lula S, Boone C, Durez P, et al
    Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review.
    Clin Exp Rheumatol. 2018 Mar 20. pii: 11621.
    PubMed     Text format     Abstract available


  183. LUBRANO E, Mesina F, Caporali R
    Clinical remission in rheumatoid arthritis and psoriatic arthritis.
    Clin Exp Rheumatol. 2018 Mar 16. pii: 12069.
    PubMed     Text format     Abstract available


  184. OMETTO F, Fedeli U, Schievano E, Botsios C, et al
    Cause-specific mortality in a large population-based cohort of patients with rheumatoid arthritis in Italy.
    Clin Exp Rheumatol. 2018 Mar 2. pii: 12288.
    PubMed     Text format     Abstract available


  185. CALABRESI E, Petrelli F, Bonifacio AF, Puxeddu I, et al
    One year in review 2018: pathogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2018;36:175-184.
    PubMed     Text format     Abstract available


  186. KEMPERS AC, Nejadnik MR, Rombouts Y, Ioan-Facsinay A, et al
    Fc gamma receptor binding profile of anti-citrullinated protein antibodies in immune complexes suggests a role for FcgammaRI in the pathogenesis of synovial inflammation.
    Clin Exp Rheumatol. 2018;36:284-293.
    PubMed     Text format     Abstract available


  187. HUANG SH, Liu GW, Li JH, Xu JH, et al
    Expression of TREM-2 and its inhibitory effects on TNF-alpha induced inflammation in fibroblast-like synoviocytes via inhibiting p38 pathway activation.
    Clin Exp Rheumatol. 2018;36:185-194.
    PubMed     Text format     Abstract available


  188. WU S, Li Y, Yao L, Li Y, et al
    Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes.
    Clin Exp Rheumatol. 2018;36:223-227.
    PubMed     Text format     Abstract available


    February 2018
  189. TINAZZI I, McGonagle D, Zabotti A, Chessa D, et al
    Comprehensive evaluation of finger flexor tendon entheseal soft tissue and bone changes by ultrasound can differentiate psoriatic arthritis and rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Feb 28. pii: 12336.
    PubMed     Text format     Abstract available


  190. XIE W, Li J, Zhang X, Li G, et al
    Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
    Clin Exp Rheumatol. 2018 Feb 28. pii: 12460.
    PubMed     Text format     Abstract available


  191. BRITSEMMER K, van Schaardenburg D, Boers M, De Cock D, et al
    Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.
    Clin Exp Rheumatol. 2018 Feb 26. pii: 11331.
    PubMed     Text format     Abstract available


  192. WEN H, Liu Y, Li J, Wei D, et al
    Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Feb 15. pii: 12260.
    PubMed     Text format     Abstract available


  193. MERDLER-RABINOWICZ R, Hassidim A, Hellou R, Merdler I, et al
    Self-reported childhood maltreatment, lifelong traumatic events and mental disorders in American and Israeli rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2018 Feb 15. pii: 12131.
    PubMed     Text format     Abstract available


  194. MANFREDI A, Sebastiani M, Cassone G, Colaci M, et al
    Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series.
    Clin Exp Rheumatol. 2018 Feb 14. pii: 12161.
    PubMed     Text format    


  195. KASHYAP S, Kumar U, Pandey AK, Kanjilal M, et al
    Functional characterisation of ADP ribosylation factor-like protein 15 in rheumatoid arthritis synovial fibroblasts.
    Clin Exp Rheumatol. 2018 Feb 14. pii: 12163.
    PubMed     Text format     Abstract available


  196. HARAGUCHI A, Yamada H, Kondo M, Okazaki K, et al
    Serum IgG ACPA-IgM RF immune complexes were detected in rheumatoid arthritis patients positive for IgM ACPA.
    Clin Exp Rheumatol. 2018 Feb 14. pii: 12212.
    PubMed     Text format     Abstract available


  197. GUDMANN NS, Hirata S, Karsdal MA, Kubo S, et al
    Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.
    Clin Exp Rheumatol. 2018 Feb 14. pii: 11742.
    PubMed     Text format     Abstract available


    January 2018
  198. ARAKI Y, Aizaki Y, Sato K, Oda H, et al
    Altered gene expression profiles of histone lysine methyltransferases and demethylases in rheumatoid arthritis synovial fibroblasts.
    Clin Exp Rheumatol. 2018 Jan 31. pii: 11175.
    PubMed     Text format     Abstract available


  199. TSUKAMOTO M, Suzuki K, Seta N, Takeuchi T, et al
    Increased circulating CD14brightCD16+ intermediate monocytes are regulated by TNF-alpha and IL-6 axis in accordance with disease activity in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Jan 31. pii: 12165.
    PubMed     Text format     Abstract available


  200. JUHL P, Thudium CS, Gudmann NS, Karsdal MA, et al
    IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADI
    Clin Exp Rheumatol. 2018 Jan 31. pii: 12085.
    PubMed     Text format     Abstract available


  201. BO M, Erre GL, Niegowska M, Piras M, et al
    Interferon regulatory factor 5 is a potential target of autoimmune response triggered by Epstein-barr virus and Mycobacterium avium subsp. paratuberculosis in rheumatoid arthritis: investigating a mechanism of molecular mimicry.
    Clin Exp Rheumatol. 2018 Jan 15. pii: 11919.
    PubMed     Text format     Abstract available


  202. IANNAZZO S, Benucci M, Favalli EG
    Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Clin Exp Rheumatol. 2018 Jan 15. pii: 12043.
    PubMed     Text format     Abstract available


  203. FERRAZ-AMARO I, Lopez-Mejias R, Tejera-Segura B, de Vera-Gonzalez AM, et al
    Amylin in the insulin resistance of patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2018 Jan 15. pii: 12060.
    PubMed     Text format     Abstract available


  204. LEI X, Li H, Zhan Y, Qu J, et al
    Predict rheumatoid arthritis conversion from undifferentiated arthritis with dynamic contrast-enhanced MRI and laboratory indexes.
    Clin Exp Rheumatol. 2018 Jan 15. pii: 12185.
    PubMed     Text format     Abstract available


  205. PAPALOPOULOS I, Fanouriakis A, Kougkas N, Flouri I, et al
    Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.
    Clin Exp Rheumatol. 2018;36:102-109.
    PubMed     Text format     Abstract available


  206. ZANKER M, Becher G, Arbach O, Maurer M, et al
    Improved adalimumab dose decision with comprehensive diagnostics data.
    Clin Exp Rheumatol. 2018;36:136-139.
    PubMed     Text format     Abstract available


  207. ATTARD L, Tadolini M, De Rose DU, Cattalini M, et al
    Overview of fever of unknown origin in adult and paediatric patients.
    Clin Exp Rheumatol. 2018;36 Suppl 110:10-24.
    PubMed     Text format     Abstract available


    December 2017
  208. GENERALI E, Carrara G, Selmi C, Verstappen SMM, et al
    Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
    Clin Exp Rheumatol. 2017 Dec 28. pii: 11415.
    PubMed     Text format     Abstract available


  209. PENG W, Liang X, Zhong Y, Zhou Y, et al
    Increased levels of serum histone H4 and activated protein C in patients with active rheumatoid arthritis.
    Clin Exp Rheumatol. 2017 Dec 27. pii: 12000.
    PubMed     Text format     Abstract available


  210. MERONI PL, Zavaglia D, Girmenia C
    Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs.
    Clin Exp Rheumatol. 2017 Dec 15. pii: 12008.
    PubMed     Text format     Abstract available


  211. NEUBAUER AS, Minartz C, Herrmann KH, Baerwald CGO, et al
    Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Clin Exp Rheumatol. 2017 Dec 15. pii: 12057.
    PubMed     Text format     Abstract available


  212. TSENG HW, Lu LY, Lam HC, Tsai KW, et al
    The influence of disease-modifying anti-rheumatic drugs and corticosteroids on the association between rheumatoid arthritis and skin cancer: a nationwide retrospective case-control study in Taiwan.
    Clin Exp Rheumatol. 2017 Dec 15. pii: 11961.
    PubMed     Text format     Abstract available


  213. HIFINGER M, Ramiro S, Putrik P, van Eijk-Hustings Y, et al
    The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands.
    Clin Exp Rheumatol. 2017 Dec 15. pii: 11705.
    PubMed     Text format     Abstract available


    November 2017
  214. GUNTER S, Robinson C, Woodiwiss AJ, Norton GR, et al
    Arterial wave reflection and subclinical atherosclerosis in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017 Nov 28. pii: 12022.
    PubMed     Text format     Abstract available


  215. MATHSSON ALM L, Fountain DL, Cadwell KK, Madrigal AM, et al
    The performance of anti-cyclic citrullinated peptide assays in diagnosing rheumatoid arthritis: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2017 Nov 28. pii: 11864.
    PubMed     Text format     Abstract available


  216. GALLI M, Antinori S, Atzeni F, Meroni L, et al
    Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2017 Nov 28. pii: 11430.
    PubMed     Text format     Abstract available


  217. LIU Y, Wu J, Shen G, Lei P, et al
    Diagnostic value of BiP or anti-BiP antibodies for rheumatoid arthritis: a meta-analysis.
    Clin Exp Rheumatol. 2017 Nov 28. pii: 11922.
    PubMed     Text format     Abstract available


  218. NAGAI T, Matsueda Y, Tomita T, Yoshikawa H, et al
    The expression of mRNA for peptidylarginine deiminase type 2 and type 4 in bone marrow CD34+ cells in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  219. THOMAS K, Flouri I, Repa A, Fragiadaki K, et al
    High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  220. PAPAGORAS C, Chrysanthopoulou A, Mitsios A, Arampatzioglou A, et al
    Autophagy inhibition in adult-onset Still's disease: still more space for hydroxychloroquine?
    Clin Exp Rheumatol. 2017;35 Suppl 108:133-134.
    PubMed     Text format    


  221. AGMON-LEVIN N, Dagan A, Peri Y, Anaya JM, et al
    The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic.
    Clin Exp Rheumatol. 2017;35:929-935.
    PubMed     Text format     Abstract available


  222. ROUHI A, Hazlewood G, Shaheen AA, Swain MG, et al
    Prevalence and risk factors for liver fibrosis detected by transient elastography or shear wave elastography in inflammatory arthritis: a systematic review.
    Clin Exp Rheumatol. 2017;35:1029-1036.
    PubMed     Text format     Abstract available


  223. HOULDER EL, Millier MJ, Highton J, Gwynne-Jones D, et al
    Expression of the genes facilitating methotrexate action within subcutaneous rheumatoid nodules.
    Clin Exp Rheumatol. 2017;35:943-947.
    PubMed     Text format     Abstract available


  224. DONGES E, Staatz CE, Benham H, Kubler P, et al
    Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
    Clin Exp Rheumatol. 2017;35:907-912.
    PubMed     Text format     Abstract available


    October 2017
  225. MA MHY, Ibrahim F, Kingsley GH, Cope A, et al
    Variable impacts of different remission states on health-related quality of life in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  226. POPE JE, Rampakakis E, Movahedi M, Cesta A, et al
    Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  227. TWEEHUYSEN L, Schraa K, Netea MG, van den Hoogen FHJ, et al
    Ex-vivo inhibited cytokine profiling explains inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    September 2017
  228. BURSKA AN, Neilan J, Chisman RE, Pitaksalee R, et al
    Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  229. FERRO F, Elefante E, Luciano N, Talarico R, et al
    One year in review 2017: novelties in the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35:721-734.
    PubMed     Text format     Abstract available


  230. CHUA JR, Gibson KA, Pincus T
    Pain and other self-report scores in patients with osteoarthritis indicate generally similar disease burden to patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35 Suppl 107:88-93.
    PubMed     Text format     Abstract available


  231. MCWILLIAMS DF, Walsh DA
    Pain mechanisms in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35 Suppl 107:94-101.
    PubMed     Text format     Abstract available


  232. BARTALESI F, Scire C, Requena-Mendez A, Abad MA, et al
    Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the
    Clin Exp Rheumatol. 2017;35:752-765.
    PubMed     Text format     Abstract available


  233. TANDON M, Perez P, Burbelo PD, Calkins C, et al
    Laser microdissection coupled with RNA-seq reveal cell-type and disease-specific markers in the salivary gland of Sjogren's syndrome patients.
    Clin Exp Rheumatol. 2017;35:777-785.
    PubMed     Text format     Abstract available


  234. CHUA JR, Castrejon I, Pincus T
    Assessment of pain and other patient symptoms in routine clinical care as quantitative, standardised, "scientific" data.
    Clin Exp Rheumatol. 2017;35 Suppl 107:13-20.
    PubMed     Text format     Abstract available


    August 2017
  235. SUN Y, Sun X, Liu Z, Wang X, et al
    MiR-338-5p suppresses rheumatoid arthritis synovial fibroblasts proliferation and invasion by targeting ADAMTS-9.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  236. SIEBUHR AS, Kjelgaard-Petersen CF, Sun S, Byrjalsen I, et al
    Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  237. MARTINEZ-ESTUPINAN L, Hernandez-Florez D, Janta I, Ovalles-Bonilla JG, et al
    An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  238. WEN W, Li Y, Cheng Y, He J, et al
    Lipopolysaccharide-binding protein is a sensitive disease activity biomarker for rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    July 2017
  239. MANARA M, Caporali R, Favalli EG, Grosso V, et al
    Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  240. GIACOMELLI R, Ruscitti P, Bombardieri S, Cuomo G, et al
    What could we learn from the sub-analysis of a single nation cohort in a worldwide study? Lessons from the results observed in the Italian cohort of the GO-MORE trial.
    Clin Exp Rheumatol. 2017;35:623-629.
    PubMed     Text format     Abstract available


  241. PERTOVAARA M, Korpela M
    RAPID3 correlates with ESSPRI and other patient-reported outcomes in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:718.
    PubMed     Text format     Abstract available


  242. BUSTAMENTE L, Matthieu B, Marquette CH, Roux C, et al
    Sarcoidosis and tocilizumab: is there a link?
    Clin Exp Rheumatol. 2017;35:716.
    PubMed     Text format     Abstract available


  243. QUARTUCCIO L, Mavragani CP, Nezos A, Gandolfo S, et al
    Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:719-720.
    PubMed     Text format     Abstract available


  244. SFIKAKIS PP, Bournia VK, Sidiropoulos P, Boumpas DT, et al
    Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Clin Exp Rheumatol. 2017;35:579-585.
    PubMed     Text format     Abstract available


  245. SAIKI O, Uda H
    Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals.
    Clin Exp Rheumatol. 2017;35:666-670.
    PubMed     Text format     Abstract available


    June 2017
  246. AYDIN SZ, Gunal EK, Ozata M, Keskin H, et al
    Six-joint ultrasound in rheumatoid arthritis: a feasible approach for implementing ultrasound in remission.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  247. LEON L, Gomez A, Vadillo C, Pato E, et al
    Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  248. BELL DA, Elhayek S, Cairns E, Barra L, et al
    Anti-homocitrullinated protein antibody isotype usage in rheumatoid arthritis and their unaffected first-degree relatives.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  249. MARRIE RA, Hitchon CA, Peschken CA, Chen H, et al
    Health care utilisation before and after intensive care unit admission in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  250. MASI AT, Rehman AA, Jorgenson LC, Aldag JC, et al
    Preclinical biomarker associations with both incident rheumatoid arthritis and its subsequent mortality: sex effects in a 41-year, community-based, case-control cohort study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  251. LESUIS N, van Vollenhoven RF, Akkermans RP, Verhoef LM, et al
    Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    May 2017
  252. HAMMER HB, Kvien TK, Terslev L
    Tenosynovitis in rheumatoid arthritis patients on biologic treatment: involvement and sensitivity to change compared to joint inflammation.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  253. DUQUENNE C, Wendling D, Sibilia J, Job-Deslandre C, et al
    Glucocorticoid-sparing effect of first-year anti-TNFalpha treatment in rheumatoid arthritis (CORPUS Cohort).
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  254. CAPORALI R, Idolazzi L, Bombardieri S, Ferraccioli G, et al
    Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  255. SEBASTIANI M, Manfredi A, Cassone G, Sandri G, et al
    Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  256. ACEBES C, Andreu JL, Balsa A, Battle E, et al
    Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach?
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  257. CODULLO V, Iannone F, Sinigaglia L, Favalli EG, et al
    Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  258. GULLICK NJ, Mian AN, Ibrahim F, Walker D, et al
    Predicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  259. RASHID T, Ebringer A, Wilson C
    The link between Proteus mirabilis, environmental factors and autoantibodies in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  260. GADEHOLT O
    Rheumatoid arthritis is not a single disease.
    Clin Exp Rheumatol. 2017;35 Suppl 104:20-21.
    PubMed     Text format     Abstract available


  261. ANGELOTTI F, Parma A, Cafaro G, Capecchi R, et al
    One year in review 2017: pathogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35:368-378.
    PubMed     Text format     Abstract available


  262. DANDA D, Sharma R, Truong D, Koelsch KA, et al
    Anti-La positive, anti-Ro negative subset of primary Sjogren's syndrome: anti-La is a reality but is the disease?
    Clin Exp Rheumatol. 2017;35:438-444.
    PubMed     Text format     Abstract available


  263. QUARTUCCIO L, Baldini C, Bartoloni E, Priori R, et al
    Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:546-547.
    PubMed     Text format     Abstract available


  264. BALDUZZI S, Scire CA, Sakellariou G, Benaglio F, et al
    In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols.
    Clin Exp Rheumatol. 2017;35:401-405.
    PubMed     Text format     Abstract available


  265. GHIGGIA A, Torta R, Tesio V, Di Tella M, et al
    Psychosomatic syndromes in fibromyalgia.
    Clin Exp Rheumatol. 2017;35 Suppl 105:106-111.
    PubMed     Text format     Abstract available


  266. BARTON JC, Bertoli LF, Barton JC, Acton RT, et al
    Fibromyalgia in 300 adult index patients with primary immunodeficiency.
    Clin Exp Rheumatol. 2017;35 Suppl 105:68-73.
    PubMed     Text format     Abstract available


  267. TORRENTE-SEGARRA V, Corominas H, Sanchez-Piedra C, Fernandez-Castro M, et al
    Fibromyalgia prevalence and associated factors in primary Sjogren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER).
    Clin Exp Rheumatol. 2017;35 Suppl 105:28-34.
    PubMed     Text format     Abstract available


    April 2017
  268. HARAOUI B, Casado G, Czirjak L, Taylor A, et al
    Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  269. FUKUYO S, Nakayamada S, Iwata S, Kubo S, et al
    Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    March 2017
  270. TIEN YC, Yen HH, Chiu YM
    Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  271. KURIYA B, Schieir O, Lin D, Xiong J, et al
    Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  272. YANG M, Galebach PJ, Signorovitch JE, Garg V, et al
    Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  273. AVILA-RIBEIRO P, Brault Y, Dougados M, Gossec L, et al
    Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  274. FERRO F, Marcucci E, Orlandi M, Baldini C, et al
    One year in review 2017: primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:179-191.
    PubMed     Text format     Abstract available


  275. PERTOVAARA M, Parkkila S, Korpela M
    Anti-carbonic anhydrase autoantibodies and serum beta-2 microglobulin correlate with the ClinESSDAI score in patients with Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:351.
    PubMed     Text format     Abstract available


  276. ARENDS S, Meiners PM, Moerman RV, Kroese FG, et al
    Physical fatigue characterises patient experience of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:255-261.
    PubMed     Text format     Abstract available


  277. HAACKE EA, van der Vegt B, Meiners PM, Vissink A, et al
    Abatacept treatment of patients with primary Sjogren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Clin Exp Rheumatol. 2017;35:317-320.
    PubMed     Text format     Abstract available


  278. LEE KE, Kang JH, Yim YR, Kim JE, et al
    Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:234-240.
    PubMed     Text format     Abstract available


  279. GIUFFRA V, Minozzi S, Vitiello A, Fornaciari A, et al
    On the history of gout: paleopathological evidence from the Medici family of Florence.
    Clin Exp Rheumatol. 2017;35:321-326.
    PubMed     Text format     Abstract available


    January 2017
  280. NICAISE C, Weichselbaum L, Schandene L, Gangji V, et al
    Phagocyte-specific S100A8/A9 is upregulated in primary Sjogren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro.
    Clin Exp Rheumatol. 2017;35:129-136.
    PubMed     Text format     Abstract available


  281. BIRT JA, Tan Y, Mozaffarian N
    Sjogren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.
    Clin Exp Rheumatol. 2017;35:98-107.
    PubMed     Text format     Abstract available


  282. ATZENI F, Gianturco L, Colombo C, Ricci C, et al
    Can speckle tracking echocardiography detect subclinical left ventricular dysfunction in patients with primary Sjogren's syndrome?
    Clin Exp Rheumatol. 2017;35:173.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: